News story

8th August 2001

MP Condemns Threat To Funding Of MS Drug

Northavon MP Steve Webb has condemned the recommendation by the National Institute for Clinical Excellence that the NHS should not fund the Multiple Sclerosis drug Beta Inteferon. The drug has been the source of controversy for several years because of its high cost and because it is effective only for a limited number of MS sufferers. Last year Steve Webb led a debate at Westminster, challenging the Government over its failure to fund the treatment. At present, Beta Inteferon is subject to a “postcode lottery” whereby whether or not a sufferer is able to access the drug depends as much on where they live as on their need. In the past, Avon Health did not fund any cases but, following pressure, it now has a strictly limited budget for the drug. After considering the cost-effectiveness of the drug for nearly two years, the Government’s National Institute is now expected to recommend that the NHS does not pay for new treatment.

Steve Webb said:

“It is clear that for a limited number of Multiple Sclerosis sufferers, this drug can make a real difference to their quality of life. I have received heart-breaking letters from local people whose doctors and consultants agree that they need this treatment and yet the Government now seems to be saying that it cannot be afforded. Beta Inteferon is being prescribed to MS sufferers throughout Europe but apparently is too expensive for the NHS. The Government must explain why our health service cannot cater for people in need”.

*** ENDS ***